Establishing best practices:
Proper injection technique for Makena® (hydroxyprogesterone caproate injection) subcutaneous auto-injector

This easy-to-follow instructional video reviews the proper technique for administering Makena for subcutaneous use. Please see Instructions For Use before administering Makena using the subcutaneous auto-injector.

Click here for full Prescribing Information Download the video

Personalized Patient Support. Healthcare Professional Resources. More Than Makena.

When you choose Makena® (hydroxyprogesterone caproate injection) for your patients, you get more than the medicine. You get one centralized resource that’s designed specifically to assist your patients throughout their Makena experience.

At Makena Care Connection®, we offer personalized support that helps make filling prescriptions easier, addresses your patients’ financial concerns, and encourages adherence to therapy. Your patients won’t just get Makena to help reduce the risk of recurrent preterm birth, but also the support when they need it.

Together we can work toward one goal—helping your patients achieve a full-term pregnancy. Our dedicated staff at Makena Care Connection is ready to connect your patients to support and work with you to help ensure a timely start to therapy.

  • Download resources that provide an overview of Makena Care Connection services and tips to help support you in prescribing Makena

Have Questions? Connect with us.

1-800-847-3418 • 8 AM–8 PM ET •

Connecting You, Your Staff, & Your Patients to Personalized Support

Rx Support

Helps make filling prescriptions easier

Each woman is unique and so are her insurance benefits. Because timely access is so important to your practice, we’ll aid in processing prescriptions, verifying insurance coverage, and obtaining prior authorizations (when applicable) to help your patients get their Makena prescription on time.

Completing the Makena Prescription Form:

  • Submit a completed Prescription Form to Makena Care Connection in one of two ways:
    • 1. Fax the prescription form to 1-800-847-3413
    • 2. Submit the e-prescription and prior authorization (if applicable) online via
  • Make a copy of patient’s insurance card
  • Encourage patient to sign the HIPAA consent
    • If patient is present at the time the prescription is completed, have her sign the paper form or electronically via eMakena
    • If the patient is not present, she can sign the form at the next visit and you can resend to Makena Care Connection. Or the patient also has the option of visiting from any device

eMakena makes things easier. Prescribe online. Connect patients to support programs. All in one place.

You can prescribe Makena through our online portal. This added resource lets you submit the prescription and prior authorization form (when applicable), track progress, and connect patients to support programs. To get started, visit

“The Makena Care Connection gives me peace of mind about access to Makena. My patients are navigated through coverage determination based on their benefits and connected to financial assistance when needed.”

–David Gandell, MD, FACOG

Financial Assistance

Committed to ensuring affordable access to Makena

We believe patients should be able to focus more on their pregnancy than the cost of their medication. To support that, AMAG Pharmaceuticals is committed to ensuring affordable access to Makena. We proactively screen and offer eligible patients financial assistance with no income caps.

*Each patient’s eligibility is evaluated on an individual basis. To be eligible, patients must meet the FDA-approved indication (pregnant with a single baby with a history of singleton spontaneous preterm birth <37 weeks)1. In compliance with federal regulations, patients insured by a government-funded program (eg, Medicaid, TRICARE, etc.) are not eligible.

If your patient feels her out-of-pocket cost is too high, she should call Makena Care Connection to see if she is eligible for financial assistance*

“I was so happy that I was approved for financial assistance. I feel very thankful that my family and I had this opportunity with the Makena Care Connection.”

– Nalleli, Makena mom

Home Injections by Healthcare Professionals

Provides injection support to patients in the comfort of their home

We can help coordinate Makena injections through a home healthcare organization. Once approved by insurance, moms prescribed Makena can choose to receive their injections by a healthcare professional in the comfort of their home or another location that’s convenient for them.

Benefits may include:

  • Supporting compliance with weekly injections
  • Addressing logistical barriers for patients
  • Simplify scheduling challenges for your office

Education & Adherence

Encourages adherence to the weekly injection schedule

We understand that moms receiving Makena injections may need some encouragement and support to stick to their weekly injection schedule, and we want to help. This free service offers educational and adherence support to encourage women to make Makena part of their pregnancy and take an active role in their health.

A level of personalized support you and your patients can expect:

  • Injection reminders to help support adherence to the weekly injection schedule
  • Educational materials that address important topics during pregnancy
  • Empowerment to help patients take an active role in their health

“Knowing she was just a phone call away gave me peace of mind. I appreciated feeling like I had someone supporting me every step of the way.”

–Shanise, Makena mom

We Speak Your Patient’s Language

We’re ready to help your patients with translation services in more than 240 languages. So communicating with moms on Makena isn’t a barrier.

Watch Deb and Nalleli's story

Makena Care Connection® offers personalized support

When Deb, a nurse practitioner, was caring for an uninsured patient who was eligible for Makena, she connected her to Makena Care Connection to ensure affordable access to treatment.


Accredo Health Group, Inc.


Cigna Tel-Drug Home Delivery Services

CVS Caremark Specialty Pharmacy



Humana Pharmacy, Inc.

Option Care

Prime Therapeutics Specialty Pharmacy™

Walgreens Specialty Pharmacy


Prime Therapeutics Specialty Pharmacy LLC (Prime Specialty Pharmacy) is a wholly owned subsidiary of Prime Therapeutics LLC.

Let your patients know that timely communication is important

  • Tell your patients to expect a phone call from Makena Care Connection and/or the specialty pharmacy
Inform your patients of an upcoming phone call from Makena Care Connection and/or a specialty pharmacy Inform your patients of an upcoming phone call from Makena Care Connection and/or a specialty pharmacy
  • Makena will not be shipped until payment is collected and the shipping address is verified

When in doubt, ask

If you or your patient is ever in doubt regarding the status of the Makena prescription, please contact Makena Care Connection at 1-800-847-3418 or email

If you know which pharmacy is dispensing your patient's prescription, you can call it directly.

Want to purchase Makena for your office? Learn how

Forms you may need to complete the Makena prescription process

Makena Prescription Form

Makena Prescription Form

To initiate the Makena prescription process via Makena Care Connection.

Makena HIPAA form

Makena Authorization for Release of Personal Health Information Form (HIPAA form)

If the patient does not sign Step 2 (Patient Authorization) of the Makena Prescription Form, this form may be completed and faxed to Makena Care Connection at a later date. The HIPAA release form allows Makena Care Connection to communicate with the healthcare provider, insurer, and specialty pharmacy on the patient's behalf. Note: this form does not need to be completed if the patient has already signed Step 2 of the Makena Prescription Form.

English Spanish

Makena (hydroxyprogesterone caproate injection) is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. The effectiveness of Makena is based on improvement in the proportion of women who delivered <37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity.

Limitation of use: While there are many risk factors for preterm birth, safety and efficacy of Makena has been demonstrated only in women with a prior spontaneous singleton preterm birth. It is not intended for use in women with multiple gestations or other risk factors for preterm birth.

Important Safety Information for Makena (hydroxyprogesterone caproate injection)
  • Do not use Makena in women with any of the following conditions:
    • Current or history of thrombosis or thromboembolic disorders
    • Known or suspected breast cancer, other hormone-sensitive cancer or history of these conditions
    • Undiagnosed abnormal vaginal bleeding unrelated to pregnancy
    • Cholestatic jaundice of pregnancy
    • Liver tumors, benign or malignant, or active liver disease
    • Uncontrolled hypertension
  • Makena should be discontinued if thrombosis or thromboembolism occurs
  • Allergic reactions, including urticaria, pruritus and angioedema, have been reported with use of Makena or with other products containing castor oil
  • Women receiving Makena should be monitored if they:
    • Are prediabetic or diabetic
    • Have conditions that may be affected by fluid retention, such as preeclampsia, epilepsy, cardiac or renal dysfunction
    • Have a history of clinical depression; Makena should be discontinued if depression recurs
    • Develop jaundice; consider whether benefit of use warrants continuation
    • Develop hypertension
  • Certain pregnancy-related fetal and maternal complications or events were numerically increased in Makena-treated subjects as compared to placebo subjects, including miscarriage (2.4% vs. 0%) and stillbirth (2% vs. 1.3%), admission for preterm labor (16% vs. 13.8%), preeclampsia or gestational hypertension (8.8% vs. 4.6%), gestational diabetes (5.6% vs. 4.6%), and oligohydramnios (3.6% vs. 1.3%)
  • The most common adverse reactions reported in ≥2% of subjects and at a higher rate in the Makena group than in the control group were injection site reactions (pain [35% vs. 33%], swelling [17% vs. 8%], pruritus [6% vs. 3%], and nodule [5% vs. 2%]), urticaria (12% vs. 11%), pruritus (8% vs. 6%), nausea (6% vs. 5%), and diarrhea (2% vs. 1%)
  • In a study where the Makena intramuscular injection was compared with placebo, the most common adverse reactions reported with Makena intramuscular injection (reported incidence in ≥2% of subjects and higher than in the control group) were: injection site reactions (pain [35%], swelling [17%], pruritus [6%], nodule [5%]), urticaria (12%), pruritus (8%), nausea (6%), and diarrhea (2%)
  • In studies where the Makena subcutaneous injection using auto-injector was compared with Makena intramuscular injection, the most common adverse reaction reported with Makena Auto-Injector use (and higher than with Makena intramuscular injection) was injection site pain (10% in one study and 34% in another)

Please see full Prescribing Information for Makena.

Reference: 1. Makena® (hydroxyprogesterone caproate injection) prescribing information, AMAG Pharmaceuticals, 2016.

Important Safety Information and Indication